VCYT Veracyte, Inc.

NASDAQ
$24.16

Veracyte, Inc. (VCYT) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is $0.31 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.4% since its last earnings release on November 4, 2026.

Veracyte Reported In-line with Expectations, Narrows Guidance
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.31 (GAAP)
Rev est $157.7M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $24.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Veracyte, Inc.

Veracyte Inc is engaged in the discovery, development and commercialization of molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment.

Sector

Healthcare

Industry

Medical Labs & Research

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.